REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedPreclinical

Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.

Xie Meiqin, Weng Jiali, Li Chenfei, Liu Qi, Feng Yi, Zhang Hai, Chang Qing, Chung Kian Fan, Adcock Ian M, Li Feng
Lung2026DOI: 10.1007/s00408-026-00875-1
N-acetylcysteineElamipretide (SS-31)

Quality Score

4/10

Citations

0

Subjects

Non-Human

PeptideVault Analysis

Study Design

Preclinical research is the foundation of the drug development pipeline. While these findings require human validation, they establish the mechanistic basis that informs dosing strategies, safety profiles, and target identification for future clinical work.

Our Assessment

Quality Assessment: 4/10 — This study contributes useful data but has methodological limitations that warrant caution. The findings are suggestive rather than definitive, and we'd recommend looking for corroborating evidence before drawing strong conclusions.

Findings in Context

The results for N-acetylcysteine, Elamipretide (SS-31) are encouraging.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Early-stage evidence for N-acetylcysteine, Elamipretide (SS-31). Interesting mechanistic insights, but we'll need human data before drawing practical conclusions.

Key Findings

The study found that both N-acetylcysteine and Elamipretide (SS-31) effectively protect against ozone-induced airway hyperresponsiveness and mucus hypersecretion in mice by reducing oxidative stress, inhibiting inflammatory pathways, and suppressing pyroptosis.

Limitations

The study is limited to a preclinical model using mice, which may not fully translate to human conditions. Additionally, the study does not explore long-term effects or potential side effects of the treatments.

Citation

Xie Meiqin, Weng Jiali, Li Chenfei et al.. (2026). Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.. Lung. https://doi.org/10.1007/s00408-026-00875-1

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.